Reply to P. Niravath et Al.

[1]  C. Osborne,et al.  Aromatase inhibitor adverse effects: are we sweeping them under the rug? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  K. Gelmon,et al.  Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Cuzick,et al.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.

[4]  R. Chlebowski,et al.  Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings , 2014, Cancer Prevention Research.

[5]  Lang Li,et al.  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Tangoku,et al.  The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia , 2011, BMC Cancer.

[7]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[8]  Yusuke Nakamura,et al.  Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.